Literature DB >> 2935320

Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma.

F Tin, N Hlaing, T Tun, S Win, R Lasserre.   

Abstract

In a field study conducted in Burma, 54 semi-immune adults suffering from falciparum malaria (mean parasite count, 15 328/mm(3) before treatment) were given a single dose of a fixed combination of 750 mg mefloquine base, 1500 mg sulfadoxine, and 75 mg pyrimethamine (3 tablets of Fansimef). All these patients were cleared of asexual parasites by day 7, giving a cure rate of 100%; the mean clearance time was 2.6 days. Reappearance of parasitaemia occurred in 10 patients on or before day 7 and persisted for one day in 8 of them and for two days in 2 patients. It eventually disappeared without further treatment. No recrudescence occurred during the follow-up time of four weeks despite the fact that there was active transmission of Plasmodium falciparum in the area throughout the whole of the study period. The drug was generally well tolerated, though mild to moderate giddiness was reported by 49 patients (90.7%) and severe giddiness by 3 patients (5.5%). Nausea occurred in 25 patients (46.3%) and vomiting in 17 (31.5%).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935320      PMCID: PMC2536381     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  Chemotherapeutic studies with mefloquine and selection of a mefloquine resistant strain of Plasmodium berghei.

Authors:  M Kazim; S K Puri; G P Dutta
Journal:  Indian J Med Res       Date:  1979-12       Impact factor: 2.375

2.  Resistance to antimalarials by Plasmodium falciparum in Burma.

Authors:  F Tin; N Hlaing
Journal:  Southeast Asian J Trop Med Public Health       Date:  1977-03       Impact factor: 0.267

3.  The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490).

Authors:  W Peters; J Portus; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1977-12

4.  In vitro mefloquine resistant Plasmodium falciparum from the Philippines.

Authors:  L L Smrkovski; R L Buck; A K Alcantara; C S Rodriguez; C V Uylance
Journal:  Lancet       Date:  1982-08-07       Impact factor: 79.321

5.  Type II mefloquine resistance in Thailand.

Authors:  E F Boudreau; H K Webster; K Pavanand; L Thosingha
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

6.  Studies on the resistance to single and combined antimalarials in the Plasmodium berghei mouse model.

Authors:  B Merkli; R W Richle
Journal:  Acta Trop       Date:  1980-09       Impact factor: 3.112

7.  Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine.

Authors:  E B Doberstyn; P Phintuyothin; S Noeypatimanondh; C Teerakiartkamjorn
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

8.  A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.

Authors:  T Harinasuta; D Bunnag; W H Wernsdorfer
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

9.  Single-dose treatment of falciparum malaria with mefloquine: field studies with different doses in semi-immune adults and children in Burma.

Authors:  F Tin; N Hlaing; R Lasserre
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

  9 in total
  3 in total

Review 1.  Triple Combination Therapy and Drug Cycling-Tangential Strategies for Countering Artemisinin Resistance.

Authors:  Bhattacharjee Dipanjan; G Shivaprakash; O Balaji
Journal:  Curr Infect Dis Rep       Date:  2017-07       Impact factor: 3.725

Review 2.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 3.  Drug resistance in malaria: a review of the west African situation.

Authors:  K O Adubofour
Journal:  J Natl Med Assoc       Date:  1992-12       Impact factor: 1.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.